公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2022 | Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals | Chen Y.-C.; Chang T.-S.; Chen C.-H.; Cheng P.-N.; Lo C.-C.; Mo L.-R.; Chen C.-T.; Huang C.-F.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; Lin H.-C.; Chen C.-Y.; Tseng K.-C.; Yu M.-L.; on behalf of TACR investigators | Viruses | 1 | 1 | |
2021 | Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan | Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; Lin H.-C.; Yu M.-L. | Liver International | 25 | 23 | |
2013 | Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis | Lin C.-W.; Lin C.-C.; Mo L.-R.; Chang C.-Y.; Perng D.-S.; Hsu C.-C.; Lo G.-H.; Chen Y.-S.; Yen Y.-C.; Hu J.-T.; Yu M.-L.; PO-HUANG LEE ; Lin J.-T.; Yang S.-S. | Journal of Hepatology | 111 | 106 | |
2021 | Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors | MING-WHEI YU ; Lin C.-L.; CHUN-JEN LIU ; Huang Y.-W.; Hu J.-T.; Wu W.-J.; Wu C.-F. | Journal of the Formosan Medical Association | 9 | 7 | |
2009 | Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus | Huang Y.-W.; CHUNG-YI HU ; CHI-LING CHEN ; Liao Y.-T.; CHUN-JEN LIU ; Lai M.-Y.; PEI-JER CHEN ; Yang S.-S.; Hu J.-T.; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Medical Virology | 7 | 6 | |
2022 | Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR) | Huang C.-F.; Tseng K.-C.; Cheng P.-N.; Hung C.-H.; Lo C.-C.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Chen C.-H.; Lee P.-L.; Lin C.-Y.; Kuo H.-T.; Chen C.-T.; Yang C.-C.; Huang J.-F.; Tai C.-M.; Hu J.-T.; Lin C.-L.; Su W.-W.; Tsai W.-L.; Huang Y.-H.; Cheng C.-Y.; Lin C.-L.; Wang C.-C.; Yang S.-S.; Mo L.-R.; Chen G.-Y.; Chang C.-C.; Wang S.-J.; Huang C.-S.; Hsieh T.-Y.; Lin C.-W.; Lee T.-H.; Chong L.-W.; Huang C.-W.; Chang S.-N.; Tsai M.-C.; SHIH-JER HSU ; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Lin H.-C.; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Chuang W.-L.; Chen C.-Y.; Yu M.-L. | Clinical Gastroenterology and Hepatology | 14 | 12 | |
2013 | Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: A nationwide cohort study | Huang Y.-W.; Wang T.-C.; Lin S.-C.; Chang H.-Y.; DING-SHINN CHEN ; Hu J.-T.; Yang S.-S.; JIA-HORNG KAO | Clinical Infectious Diseases | 81 | 75 | |
2014 | Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study | Huang Y.-W.; Yang S.-S.; Fu S.-C.; Wang T.-C.; Hsu C.-K.; DING-SHINN CHEN ; Hu J.-T.; JIA-HORNG KAO | Hepatology | 95 | 87 | |
2015 | Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: A nationwide cohort study | Fu S.-C.; Huang Y.-W.; Wang T.-C.; Hu J.-T.; DING-SHINN CHEN ; Yang S.-S. | Alimentary Pharmacology and Therapeutics | 39 | 38 | |
2015 | Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: A nation-wide cohort study | YI-WEN HUANG ; Wang T.-C.; Yang S.-S.; Lin S.-Y.; Fu S.-C.; Hu J.-T.; CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Alimentary Pharmacology and Therapeutics | 23 | 23 | |
2006 | Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study | CHUN-JEN LIU ; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; CHI-LING CHEN ; PEI-JER CHEN ; JIA-HORNG KAO ; DING-SHINN CHEN | Hepatology | 41 | 35 | |
2022 | Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan | Lo C.-C.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Chen C.-Y.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; Chuang W.-L.; Lin H.-C.; JIA-HORNG KAO ; Yu M.-L.; TACR investigators | Journal of the Formosan Medical Association | 3 | 0 | |
2020 | Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma | Huang B.-Y.; Tsai M.-R.; Hsu J.-K.; CHING-YU LIN ; Lin C.-L.; Hu J.-T.; Huang Y.-W.; CHUN-JEN LIU ; Wu W.-J.; Wu C.-F.; Sung F.-Y.; PEI-JER CHEN ; Liang H.-J.; Lin S.-M.; MING-WHEI YU | Molecular Carcinogenesis | 9 | 6 | |
2018 | Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | Wang, CK; MING-CHIH HO ; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN ; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; PO-HUANG LEE ; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Lin S.-M.; GUAN-TARN HUANG ; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG ; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG ; CHIUN HSU ; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG ; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI ; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Surveillance group; Diagnosis group; Staging group; Surgery group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group | Journal of the Formosan Medical Association = Taiwan yi zhi | 90 | 87 | |
2021 | Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan | Huang C.-F.; Kuo H.-T.; Chang T.-S.; Lo C.-C.; Hung C.-H.; Huang C.-W.; Chong L.-W.; Cheng P.-N.; Yeh M.-L.; Peng C.-Y.; Cheng C.-Y.; Huang J.-F.; Bair M.-J.; Lin C.-L.; Yang C.-C.; Wang S.-J.; Hsieh T.-Y.; Lee T.-H.; Lee P.-L.; Wu W.-C.; Lin C.-L.; Su W.-W.; Yang S.-S.; Wang C.-C.; Hu J.-T.; Mo L.-R.; Chen C.-T.; Huang Y.-H.; Chang C.-C.; Huang C.-S.; Chen G.-Y.; Kao C.-N.; Tai C.-M.; CHUN-JEN LIU ; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; JIA-HORNG KAO ; Lin H.-C.; Chuang W.-L.; Chen C.-Y.; Tseng K.-C.; Yu M.-L. | Scientific Reports | 9 | 5 | |
2015 | On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy | YI-WEN HUANG ; Takahashi S.; Tsuge M.; CHI-LING CHEN ; Wang T.-C.; Abe H.; Hu J.-T.; DING-SHINN CHEN ; Yang S.-S.; Chayama K.; JIA-HORNG KAO | Antiviral Therapy | 61 | 57 | |
2013 | Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy | Huang Y.-W.; Lin S.-C.; SHU-CHEN WEI ; Hu J.-T.; Chang H.-Y.; Huang S.-H.; DING-SHINN CHEN ; PEI-JER CHEN ; PING-NING HSU ; Yang S.-S.; JIA-HORNG KAO | Antiviral Therapy | 44 | 37 | |
2014 | Reduced toll-like receptor 9 expression on peripheral C D14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy | YI-WEN HUANG ; Hsu C.-K.; Lin S.-C.; SHU-CHEN WEI ; Hu J.-T.; Chang H.-Y.; Liang C.-W.; DING-SHINN CHEN ; PEI-JER CHEN ; PING-NING HSU ; Yang S.-S.; JIA-HORNG KAO | Antiviral Therapy | 20 | 17 | |
2019 | Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions | Chou Y.-H.; JA-DER LIANG ; Wang S.-Y.; SHIH-JER HSU ; Hu J.-T.; Yang S.-S.; Wang H.-K.; Lee T.-Y.; Tiu C.-M. | Journal of Medical Ultrasound | 17 | 15 | |
2022 | Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan | Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; CHUN-JEN LIU ; Dai C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L.; Yu M.-L.; TACR investigators | Infectious Diseases and Therapy | 9 | 8 | |